ASCO24 trials summarized by Arndt Vogel

Arndt Vogel shared on X/Twitter:

“NIVO + IPI vs LEN (90%) or SORA as 1st line treatment for HCC

• Exciting times: More and more options in 1st line HCC
• Clear improvement in OS with ICI based therapy and sequential therapy
• Now, we need biomarkers to guide treatment decisions.

Peri-operative nivolumab and ipilimumab esophagealv and GEJ adenocarcinoma

ECOG-ACRIN EA2174, 275 patients

• pCR rate 21.0% vs 24.8%
• Surgical complications 28.7% vs 25.4%
• High rate of drop out after surgery
• Nivo to neoadjuvant chemoradiotherapy does not improve pCR rate.

Early results of the PASS-01 trial: PDAC signature stratification for treatment-01

Phase 2, 160 patients, 1st line GnP vs mFFX, 2nd line based on WGS/transcriptom

• ORR 30% vs 24%, mPFS 5.4 vs 4.4 months, mOS 9.7 vs 8.4 months
• MTB guided 2nd line treatment, PDOs in 50%
• Impressive multi-omic profiling study to guide treatment decisions.

Ramucirumab + paclitaxel as switch maintenance vs chemotherapy continuation in GC and GEJ cancer

ARMANI phase III trial, 197 patients

• ORR 19 vs 15.7%
• mPFS 6.6 vs. 3.5 months
• mOS 12.6 vs. 10.4 months
• AE ≥3 40.4 vs. 20.7%
• Switch maintenance after 3 months FOLFOX valid option for (marker negative) GC.

NIVO + IPI vs LEN (90%) or SORA as 1st line treatment for HCC

CHECKMATE 9DW, 668 patients

• ORR 36 vs 13%, DoR 30 vs 13 months
• mPFS 9.1 vs 9.1 months
• mOS 23.7 vs 20.6 months
• More options in 1st line HCC, very good data for Lenva and Nivo/Ipi.

Chemotherapy vs chemotherapy followed by resection in limited-metastatic GC and GEJ cancer

RENAISSANCE phase III trial, 139 patients

• Surgery in 91% of pts, R0 82%
• mOS 18.5 vs 23.6 mo, crossing KM curves
• No survival benefit, increased early mortality in surgery arm, patients with RPLN metastasis may benefit.”

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.

He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.